Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Illinois bans ephedra

This article was originally published in The Tan Sheet

Executive Summary

Legislation banning sale of "any dietary supplement containing any quantity of ephedra or ephedrine alkaloids to any person" in Illinois passes both houses of General Assembly May 15. Violators would be subject to fines of up to $5,000 and could face up to one year in jail for first offense. Gov. Rod Blagojevich (D), who urged the bill's passage, has pledged to sign the legislation. In May 16 1press release, ephedra foe Sen. Dick Durbin (D-Ill.) calls bill "stark and compelling evidence of the federal government's failure to take decisive action against ephedra." Durbin sends seventh letter to HHS Secretary Tommy Thompson urging nationwide ban of herbal...

You may also be interested in...



CVS discontinues ephedra

Chain drugstore will remove all ephedra-containing product inventory from its 4,100 stores beginning Aug. 1 and instead offer more ephedra-free items "to continue meeting the weight-loss needs of its customers," firm says July 11. Although CVS believes ephedra products are safe when used as directed, it decided to halt sales of the herbal because "several communities where we have stores [are] taking steps to ban products with ephedra." Illinois has banned the ingredient and New York, California have legislation pending (1"The Tan Sheet" May 26, 2003, In Brief)...

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel